Medical Information Only. Always consult your healthcare provider before enrolling in any clinical trial.
NCT03044977 · ClinicalTrials.gov registry record · Early Phase 1
Study to Evaluate the Safety of Combining Two Radionuclide Therapies to Treat Mid-gut Neuroendocrine Tumors
A Early Phase 1 study of Neuroendocrine Tumor, Malignant and Neuroendocrine Tumor Gastrointestinal, Hormone-Secreting, sponsored by David Bushnell.
- Active
- Registry status
- Early Phase 1
- Development phase
- 20
- Enrollment target
- 1
- Study location
NCT03044977: Active Early Phase 1 study of Neuroendocrine Tumor, Malignant and Neuroendocrine Tumor Gastrointestinal, Hormone-Secreting, sponsored by David Bushnell.
NCT03044977 is a Early Phase 1 study of Neuroendocrine Tumor, Malignant and Neuroendocrine Tumor Gastrointestinal, Hormone-Secreting that is active but no longer recruiting, run by David Bushnell. The registered enrollment target is 20 participants, below the 53-participant average among 2,764 other Early Phase 1 trials with a reported enrollment target (62% lower). The trial reports 1 study location across 1 state. According to ClinicalTrials.gov, the official US trial registry.
The verdict
NCT03044977, a Early Phase 1 study of Neuroendocrine Tumor, Malignant and Neuroendocrine Tumor Gastrointestinal, Hormone-Secreting, is active but no longer recruiting, sponsored by David Bushnell.
- ACTIVE NOT RECRUITING
- Registry status
- Early Phase 1
- Development phase
- 20 participants
- Enrollment target
- 1
- Study location
Study Summary
This study is designed to identify the best tolerated doses of \[131\]Iodine-MIBG and \[90\]Yttrium-DOTATOC when co-administered to treat midgut neuroendocrine tumors. These drugs (131I-MIBG, 90Y-DOTATOC) are radioactive drugs, known as radionuclide therapy. Currently, the safest and best tolerated doses of these drugs (when combined together) is unknown.
Primary Outcome
Evaluate renal toxicity using eGFR measurement
Conditions Studied
Interventions
- DRUG 90Y-DOTA-3-Tyr-Octreotide
- DRUG 131I-MIBG
Study Locations (1)
Iowa
- Holden Comprehensive Cancer Center - Iowa City
Trial Details
| Field | Value |
|---|---|
| Enrollment Target | 20 participants |
| Start Date | 2017-05-07 |
| Est. Completion | 2027-12 |
| Phase | Early Phase 1 |
What the registry record for NCT03044977 still lists
NCT03044977 is an interventional study that assigns participants to a tested intervention. The registry caps enrollment at 20 participants, a relatively small participant target, below the 53-participant average among 2,764 other Early Phase 1 trials with a reported enrollment target (62% lower).
The record links to 2 conditions, with Neuroendocrine Tumor, Malignant appearing as the primary indexed condition, and to 2 interventions - of which 90Y-DOTA-3-Tyr-Octreotide is the first listed.
NCT03044977 reports a single indexed study location in Iowa.
Frequently Asked Questions
What is clinical trial NCT03044977 about?
NCT03044977 is a clinical study titled "Study to Evaluate the Safety of Combining Two Radionuclide Therapies to Treat Mid-gut Neuroendocrine Tumors". This study is designed to identify the best tolerated doses of \[131\]Iodine-MIBG and \[90\]Yttrium-DOTATOC when co-administered to treat midgut neuroendocrine tumors. These drugs (131I-MIBG, 90Y-DOTATOC) are radioactive drugs, known as radionuclide therapy. Currently, the safest and best tolerated ...
What is the current status of trial NCT03044977?
This trial is currently active not recruiting. It is a Early Phase 1 study. The enrollment target is 20 participants. The study started on 2017-05-07. Estimated completion is 2027-12.
What conditions does trial NCT03044977 study?
This clinical trial studies the following conditions: Neuroendocrine Tumor, Malignant, Neuroendocrine Tumor Gastrointestinal, Hormone-Secreting.
What interventions are being tested in trial NCT03044977?
The interventions under investigation include: 90Y-DOTA-3-Tyr-Octreotide (DRUG), 131I-MIBG (DRUG).
Who is sponsoring clinical trial NCT03044977?
This trial is sponsored by David Bushnell, which has 3 total clinical trials registered on ClinicalTrials.gov.
Where is trial NCT03044977 being conducted?
This trial has 1 study location across Iowa. Contact the study sites directly through ClinicalTrials.gov for enrollment availability.
Learn More About Clinical Trials
How this trial's enrollment target compares
Where NCT03044977's enrollment target sits among peer trials
20 1157th of 2000 higher than 710 of 2,000 other Early Phase 1 trials
participants (enrollment target), bucketed by value
Each bar is a band; taller bars hold more other Early Phase 1 trials. The dashed line + filled bar mark this entry. Hover or tap any bar for its full count and share, and where it sits relative to this entry.
Source ClinicalTrials.gov registry export · 2026-08-08
Nationwide trials with similar profiles
Cross-condition peers matched on enrollment target and registry start date, not the same-condition list above.
Similar enrollment target
- NCT00573339 · 20 participants
Cardiac Magnetic Resonance Imaging (MRI) Normal Reference Control Group Testing
- NCT00692939 · 20 participants · Phase 1
Autologous Stem Cell Transplantation for Crohn's Disease
- NCT00967785 · 20 participants · Phase 1
A Phase I Study of Mozobil in the Treatment of Patients With WHIMS
- NCT01406691 · 20 participants · Phase 4
Light Flashes to Treat Delayed Sleep Phase Disorder (DSPD)
Similar registry start date
- NCT05962346 · started 2026-12 · NA
Fetal Endoscopic Tracheal Occlusion for Congenital Diaphragmatic Hernia
- NCT07125183 · started 2026-12 · Phase 2
Study on Efficacy and Tolerability of Weekly Doxorubicin in Elderly Patients With Advanced or Metastatic Leiomyosarcoma
- NCT07292298 · started 2026-11 · Phase 2
Phase 2 Single-Arm Rectal Cancer Brachytherapy for Patients With Low-Lying Residual Adenocarcinoma After Total Neoadjuvant Therapy to Improve Organ Preservation Rates
- NCT04263285 · started 2026-10 · NA
Treatment of Depression Post-SCI